(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
Top 15 Web-based Entertainment Stages for Individual Marking- 5 Fundamental Ways to employ a Criminal Legal counselor
- Benedict Cumberbatch on letting go after a heavy role — and finding joy in ‘Elf’
- Brexit's Effect on New York's Ascent as a Main Monetary Center
- The Best 20 Tunes that Characterized an Age
- Ageless Tastefulness: An Outline of Valuable Gemstones and Adornments
- 'Stranger Things' character guide: The nerds, the newcomers and the rest of the Season 5 cast
- Wedding trip Objections in the US
- Well known Worldwide Caf\u00e9s to Experience
